Interferon-β, retinoids, and tamoxifen in the treatment of metastatic breast cancer

A phase II study

F. Recchia, G. Sica, S. De Filippis, S. Discepoli, S. Rea, P. Torchio, L. Frati

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Based on the additive or synergistic antiproliferative effect of interferon and tamoxifen on breast cancer cell lines and on preclinical and clinical data on retinoids alone and in combination with antiestrogen or interferon, we designed a pilot phase II study to test the toxicity of simultaneous administration of interferon-β (IFN-β), retinoids (R), and tamoxifen (TAM) and the efficacy of this combination as salvage therapy in a group of patients with metastatic breast cancer (MBC). A total of 49 stage IV breast cancer patients, 11 pretreated with hormones, 26 with chemotherapy, and 12 with both, received 30 mg TAM and two dose levels of IFN-β and retinyl palmitate. Among 49 evaluable patients, 27 achieved a clinical response (55%; 95% CI 41-69%), 10 had stable disease (20%), and in 12 (25%) the disease progressed. Toxicity with both dose levels was moderate and mainly hepatic. Median response duration, not statistically different in estrogen receptor-positive and negative patients, was 31.4 months (range 4.9- 67). Median overall survival was 19.2 months (range 2-69). We have shown that long-term administration of TAM, IFN-β, and retinyl palmitate is feasible with moderate toxicity. We have also demonstrated that this regimen is active in pretreated MBC patients and that responses are not influenced by receptor status.

Original languageEnglish
Pages (from-to)605-610
Number of pages6
JournalJournal of Interferon and Cytokine Research
Volume15
Issue number7
Publication statusPublished - 1995

Fingerprint

Retinoids
Tamoxifen
Interferons
Breast Neoplasms
Therapeutics
Toxicity Tests
Salvage Therapy
Estrogen Receptor Modulators
Estrogen Receptors
Hormones
Drug Therapy
Cell Line
Survival
Liver
retinol palmitate

ASJC Scopus subject areas

  • Cell Biology
  • Immunology
  • Virology

Cite this

Interferon-β, retinoids, and tamoxifen in the treatment of metastatic breast cancer : A phase II study. / Recchia, F.; Sica, G.; De Filippis, S.; Discepoli, S.; Rea, S.; Torchio, P.; Frati, L.

In: Journal of Interferon and Cytokine Research, Vol. 15, No. 7, 1995, p. 605-610.

Research output: Contribution to journalArticle

Recchia, F, Sica, G, De Filippis, S, Discepoli, S, Rea, S, Torchio, P & Frati, L 1995, 'Interferon-β, retinoids, and tamoxifen in the treatment of metastatic breast cancer: A phase II study', Journal of Interferon and Cytokine Research, vol. 15, no. 7, pp. 605-610.
Recchia, F. ; Sica, G. ; De Filippis, S. ; Discepoli, S. ; Rea, S. ; Torchio, P. ; Frati, L. / Interferon-β, retinoids, and tamoxifen in the treatment of metastatic breast cancer : A phase II study. In: Journal of Interferon and Cytokine Research. 1995 ; Vol. 15, No. 7. pp. 605-610.
@article{82c3b3ae11454660b3a1c0b119c485d7,
title = "Interferon-β, retinoids, and tamoxifen in the treatment of metastatic breast cancer: A phase II study",
abstract = "Based on the additive or synergistic antiproliferative effect of interferon and tamoxifen on breast cancer cell lines and on preclinical and clinical data on retinoids alone and in combination with antiestrogen or interferon, we designed a pilot phase II study to test the toxicity of simultaneous administration of interferon-β (IFN-β), retinoids (R), and tamoxifen (TAM) and the efficacy of this combination as salvage therapy in a group of patients with metastatic breast cancer (MBC). A total of 49 stage IV breast cancer patients, 11 pretreated with hormones, 26 with chemotherapy, and 12 with both, received 30 mg TAM and two dose levels of IFN-β and retinyl palmitate. Among 49 evaluable patients, 27 achieved a clinical response (55{\%}; 95{\%} CI 41-69{\%}), 10 had stable disease (20{\%}), and in 12 (25{\%}) the disease progressed. Toxicity with both dose levels was moderate and mainly hepatic. Median response duration, not statistically different in estrogen receptor-positive and negative patients, was 31.4 months (range 4.9- 67). Median overall survival was 19.2 months (range 2-69). We have shown that long-term administration of TAM, IFN-β, and retinyl palmitate is feasible with moderate toxicity. We have also demonstrated that this regimen is active in pretreated MBC patients and that responses are not influenced by receptor status.",
author = "F. Recchia and G. Sica and {De Filippis}, S. and S. Discepoli and S. Rea and P. Torchio and L. Frati",
year = "1995",
language = "English",
volume = "15",
pages = "605--610",
journal = "Journal of Interferon and Cytokine Research",
issn = "1079-9907",
publisher = "Mary Ann Liebert Inc.",
number = "7",

}

TY - JOUR

T1 - Interferon-β, retinoids, and tamoxifen in the treatment of metastatic breast cancer

T2 - A phase II study

AU - Recchia, F.

AU - Sica, G.

AU - De Filippis, S.

AU - Discepoli, S.

AU - Rea, S.

AU - Torchio, P.

AU - Frati, L.

PY - 1995

Y1 - 1995

N2 - Based on the additive or synergistic antiproliferative effect of interferon and tamoxifen on breast cancer cell lines and on preclinical and clinical data on retinoids alone and in combination with antiestrogen or interferon, we designed a pilot phase II study to test the toxicity of simultaneous administration of interferon-β (IFN-β), retinoids (R), and tamoxifen (TAM) and the efficacy of this combination as salvage therapy in a group of patients with metastatic breast cancer (MBC). A total of 49 stage IV breast cancer patients, 11 pretreated with hormones, 26 with chemotherapy, and 12 with both, received 30 mg TAM and two dose levels of IFN-β and retinyl palmitate. Among 49 evaluable patients, 27 achieved a clinical response (55%; 95% CI 41-69%), 10 had stable disease (20%), and in 12 (25%) the disease progressed. Toxicity with both dose levels was moderate and mainly hepatic. Median response duration, not statistically different in estrogen receptor-positive and negative patients, was 31.4 months (range 4.9- 67). Median overall survival was 19.2 months (range 2-69). We have shown that long-term administration of TAM, IFN-β, and retinyl palmitate is feasible with moderate toxicity. We have also demonstrated that this regimen is active in pretreated MBC patients and that responses are not influenced by receptor status.

AB - Based on the additive or synergistic antiproliferative effect of interferon and tamoxifen on breast cancer cell lines and on preclinical and clinical data on retinoids alone and in combination with antiestrogen or interferon, we designed a pilot phase II study to test the toxicity of simultaneous administration of interferon-β (IFN-β), retinoids (R), and tamoxifen (TAM) and the efficacy of this combination as salvage therapy in a group of patients with metastatic breast cancer (MBC). A total of 49 stage IV breast cancer patients, 11 pretreated with hormones, 26 with chemotherapy, and 12 with both, received 30 mg TAM and two dose levels of IFN-β and retinyl palmitate. Among 49 evaluable patients, 27 achieved a clinical response (55%; 95% CI 41-69%), 10 had stable disease (20%), and in 12 (25%) the disease progressed. Toxicity with both dose levels was moderate and mainly hepatic. Median response duration, not statistically different in estrogen receptor-positive and negative patients, was 31.4 months (range 4.9- 67). Median overall survival was 19.2 months (range 2-69). We have shown that long-term administration of TAM, IFN-β, and retinyl palmitate is feasible with moderate toxicity. We have also demonstrated that this regimen is active in pretreated MBC patients and that responses are not influenced by receptor status.

UR - http://www.scopus.com/inward/record.url?scp=0029164679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029164679&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 605

EP - 610

JO - Journal of Interferon and Cytokine Research

JF - Journal of Interferon and Cytokine Research

SN - 1079-9907

IS - 7

ER -